Vir Biotechnology Completes $150 Million Capital Raise, Strengthens Development Pipeline

Vir Biotechnology (VIR), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, has successfully completed a public offering that underscores investor confidence in its expanding pipeline. The offering priced 17.65 million shares at $8.50 per share, generating $150 million in gross proceeds to fuel the company’s ambitious development agenda.

Offering Details and Market Reception

The biotech firm priced its offering through prominent financial institutions including Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, and Barclays acting as book-running managers. Underwriters received a 30-day greenshoe option to purchase an additional 2.65 million shares at the offering price. The offering closed in late February 2026, marking a significant capital infusion for the company’s advancement efforts.

Following the announcement, VIR shares initially traded lower, reflecting typical market dynamics around dilution events. The stock showed volatility, with historical trading ranging between $4.16 and $10.94 over the preceding year, reflecting the inherent uncertainties associated with clinical-stage biotech companies.

Vir’s Clinical Pipeline and Near-Term Catalysts

The company’s research focus spans multiple therapeutic areas with a portfolio of innovative T-cell engaging programs. Vir’s most advanced program, Tobevibart + Elebsiran for chronic hepatitis delta, is progressing through Phase 3 ECLIPSE trials with topline efficacy data anticipated between the fourth quarter of 2026 and first quarter of 2027—a critical milestone that could reshape treatment options for this difficult-to-treat disease.

In oncology, VIR-5818, a HER2-targeted dual-masked T-cell engager being studied alongside pembrolizumab, expects clinical response data in the second half of 2026. The company’s PSMA-targeting candidate, VIR-5500, represents another significant development vector, with combination dose-expansion studies planned to initiate in mid-2026 followed by pivotal Phase 3 trials launching in 2027.

Strategic Partnership with Astellas Pharma

Recently, Vir announced a global strategic collaboration with Astellas Pharma focusing on VIR-5500 for metastatic castration-resistant prostate cancer (mCRPC) and related indications. This partnership validates the company’s T-cell engager approach and provides additional financial and operational support for advancing VIR-5500 through pivotal trials, while enabling Vir to pursue its broader pipeline more aggressively.

Financial Position and Operational Runway

Vir closed 2025 with $781.6 million in cash, cash equivalents, and investments—a position strengthened by the newly completed $150 million offering. Management projects this financial base will fund ongoing operations and clinical development through the second quarter of 2028, providing adequate runway for advancing multiple programs through key inflection points. This substantial cash cushion positions Vir favorably to execute its clinical strategy without near-term financing pressure and supports the company’s ability to pursue additional partnerships or acquisitions if strategic opportunities emerge.